Intravenous Infusion Of Arginine Vasopressin Research Articles

Unlike arginine vasopressin, the selective V1a receptor agonist FE 202158 does not cause procoagulant effects by releasing von Willebrand factor.

To compare the effects on von Willebrand factor release of the mixed vasopressin type 1a and type 2 receptor agonist arginine vasopressin and the selective vasopressin type 1a receptor agonist FE 202158, [Phe2,Ile3,Hgn4,Orn(iPr)8]vasopressin, at doses required for the treatment of septic shock. Prospective, randomized, controlled laboratory experiment. University animal research facility. Twenty-four chronically instrumented sheep. After a 5-day recovery from instrumentation, sheep were randomly assigned to receive a single intravenous bolus of the selective vasopressin type 2 receptor agonist desmopressin (1 nmol·kg(-1)) or continuous intravenous infusions of arginine vasopressin (3 pmol·kg(-1)·min(-1)), the selective vasopressin type 1a receptor agonist FE 202158 (10 pmol·kg(-1)·min(-1)), or vehicle (0.9% NaCl) (n = 6 each). The von Willebrand factor antigen activity relative to hemoglobin concentration (vWF:Ag/Hb ratio) was measured at different time points during the 120-min study period. Maximal vWF:Ag/Hb ratio expressed as percentage of baseline level was significantly increased compared to vehicle-infused animals (3 ± 2%) in the desmopressin (40 ± 6%, p < .001) and arginine vasopressin groups (25 ± 4%, p < .001). The ratio for the FE 202158 group was not statistically different from the sham group (9 ± 2%, p = .208). Notably, maximal vWF:Ag/Hb ratio was lower in the FE 202158 than the arginine vasopressin group (p < .005). Unlike the mixed vasopressin type 1a receptor/vasopressin type 2 receptor agonist arginine vasopressin, the selective vasopressin type 1a receptor agonist FE 202158 does not release von Willebrand factor. Because von Willebrand factor is involved in coagulatory and inflammatory pathways during septic shock, future studies should clarify the role of the vasopressin type 2 receptor-mediated von Willebrand factor increase by arginine vasopressin and the potential benefit of selective vasopressin type 1a receptor-agonists like FE 202158.

Detectability of Vasopressin in Continuous Venovenous Hemodialysis Effluent of Patients with Vasodilatory Shock Treated with Exogenous Arginine Vasopressin

To determine whether vasopressin is detectable in the continuous venovenous hemodialysis (CVVHD) effluent of patients receiving exogenous arginine vasopressin, and to determine whether treatment-specific factors are associated with vasopressin levels in CVVHD effluent. DESIGN. Prospective observational study. SETTING. Intensive care units of a tertiary care academic medical center. PATIENTS. Twenty-seven adults with vasodilatory shock who received a stable-dose continuous intravenous infusion of arginine vasopressin with concomitant uninterrupted CVVHD for at least 4 hours between September 2008 and May 2010. MEASUREMENTS AND MAIN RESULTS. Vasopressin levels in CVVHD effluent were assessed by radioimmunoassay. Statistical analysis was performed with analysis of variance and Pearson correlation. A multivariate linear regression was used to assess for independent factors associated with vasopressin levels in CVVHD effluent. The CVVHD effluent of all patients was assessed for vasopressin levels. The median exogenous arginine vasopressin dose was 0.03 unit/minute (range 0.02-0.18 unit/min), whereas the median CVVHD effluent flow rate was 22.6 ml/kg/hour (interquartile range [IQR] 21.5-26.8 ml/kg/hr). Vasopressin was detectable in all effluent samples (median 88.8 pg/ml, IQR 36.4-113.7 pg/ml). There were no significant differences in CVVHD effluent vasopressin levels among CVVHD filter types (p=0.39). The CVVHD effluent vasopressin levels correlated with exogenous arginine vasopressin dose (r2=0.49, p<0.001). After adjustment for CVVHD effluent flow rate and administration of corticosteroids, with multivariate linear regression, only exogenous arginine vasopressin dose was independently associated with CVVHD effluent vasopressin level. CONCLUSION. Vasopressin is detectable in CVVHD effluent, suggesting that it is removed by CVVHD. In addition, exogenous arginine vasopressin infusion dose is independently associated with CVVHD effluent vasopressin level.

Lack of an Effect of Body Mass on the Hemodynamic Response to Arginine Vasopressin During Septic Shock

To determine whether body mass alters the effectiveness of a fixed-dose infusion of arginine vasopressin. Retrospective medical record review. All intensive care units of a tertiary medical center. Sixty-six mechanically ventilated patients who received a fixed-dose intravenous infusion of arginine vasopressin at 0.04 U/minute as the sole agent for hemodynamic support during septic shock. Patients were divided into four groups on the basis of body mass index. Effectiveness was measured as hemodynamic stability, which was defined as the proportion of patients achieving a mean arterial pressure (MAP) of 65 mm Hg or higher, the magnitude of the change in MAP at 1 hour, and the need for additional rescue vasopressors. Secondary outcomes included mortality and length of stay. Baseline characteristics of all four groups were comparable for age, sex, and severity of illness determined by using Acute Physiology and Chronic Health Evaluation II (APACHE II), Simplified Acute Physiology II (SAPS II), and Sequential Organ Failure Assessment (SOFA) scores. The only significant differences in baseline characteristics among the groups were in their central venous pressures. The four groups similarly achieved hemodynamic stability at 1 hour after the administration of arginine vasopressin (p=0.41). We observed no significant differences among groups in the magnitude of MAP change (p=0.62), need for rescue catecholamine vasopressors (p=0.17), 28-day mortality rates (p=0.31), or length of stay in the intensive care unit (p=0.43). Body mass index did not alter the effects of arginine vasopressin on hemodynamic stability or changes in MAP when the drug was administered as a fixed-dose infusion of 0.04 U/minute. Our results do not support weight-based dosing of vasopressin, unlike the dosing for catecholamine vasopressors.

Lung Fluid Balance During Development

After completing this article, readers should be able to: 1. Describe the major driving forces for liquid formation in and liquid removal from the lumen of the fetal lung. 2. Delineate the role of a normal volume of liquid within the lumen of the fetal lung for normal lung growth during development. 3. Describe the effects of labor on Na,K-ATPase activity in lung epithelial cells and clearance of lung liquid after birth. 4. Explain the route by which most residual liquid drains from the lung. 5. List the conditions associated with preterm birth that may contribute to delayed removal of fetal lung liquid. Curious students of mammalian development recognized more than a century ago that the lungs are filled with liquid during fetal life, (1) but the origin of that liquid remained obscure until 1948, when an unexpected discovery by two French scientists dispelled the prevailing view that fetal lung liquid derived from intrauterine inhalation of amniotic fluid. In studies designed to explore the ontogeny of the pituitary-adrenal axis, tracheal ligation of fetal rabbits for 9 days resulted in fluid distention of the lungs. (2) This serendipitous finding, subsequently confirmed and embellished by others, (3)(4)(5) established that the fetal lung itself, rather than the amniotic sac, is the source of the liquid that fills the lung during development. This liquid forms a slowly expanding structural template that prevents collapse and promotes growth of the fetal lung. Subsequent studies, conducted mostly with sheep, showed that liquid in the lumen of the fetal lung forms as a result of chloride secretion in the respiratory epithelium, (6)(7) a process that can be inhibited by diuretics that block Na,K-2Cl cotransport. (8)(9) In vitro experiments using cultured explants of lung tissue and monolayers of epithelial cells harvested from human fetal lung have …

Nitric oxide in the renal medulla protects from vasopressin-induced hypertension.

In the present study, we assessed whether activation of the nitric oxide (NO) system within the renal medulla could serve as a buffer against the chronic hypertensive effects of arginine vasopressin (AVP). NO concentration in the renal medulla of Sprague-Dawley rats was measured with in vivo microdialysis/oxyhemoglobin NO trapping. The results showed that medullary interstitial [NO] was increased after 2 hours of AVP infusion and remained elevated even after 10 days (by 62+/-8% and 42+/-13%, respectively). Western blot analysis showed that 2 days of AVP infusion was insufficient to increase protein expression of any of the NO synthase (NOS) isoforms, but after 10 days of AVP infusion, endothelial NOS expression was significantly increased in the inner medulla with no significant changes in noninducible NOS and inducible NOS levels. When renal medullary NOS enzyme activity was blunted with a nonpressor dose of N(G)-nitro-L-arginine methyl ester (75 microg. kg(-1). h(-1)) that was chronically infused locally into the renal medulla, intravenous AVP infusion (which was shown earlier to be subpressor in chronic studies) produced a sustained elevation in arterial pressure (from 107+/-2 to 121+/-2 mm Hg). These data indicate that chronic elevations in plasma AVP enhance renal medullary endothelial NOS protein expression, which enables sustained elevations of NO concentrations in this region of the kidney to buffer the hypertensive effects of AVP.

Radiotelemetric versus externalized catheter monitoring of blood pressure: effect of vasopressin in spontaneous hypertension

The changes in arterial pressure that follow withdrawal of a 3-h intravenous infusion of arginine vasopressin (AVP; 20 ng/kg/min) in spontaneously hypertensive rats (SHR) were monitored by radiotelemetry or conventional externalized femoral arterial catheters connected to pressure transducers. Baseline control arterial pressure was lower in the telemetry group compared to the externalized group. After withdrawal of the AVP infusion, blood pressure fell below preinfusion levels in both groups but the decrease was much less in the telemetry group. Strikingly, absolute blood pressure values recorded both during and after the vasopressin infusion were remarkably similar in the two groups. Responses in rats with externalized catheters implanted 7 days before infusion of AVP, a protocol similar to the telemetry group, were similar to those in rats with catheters implanted 24 h earlier. Blood pressure remained decreased in SHR infused with AVP for several days with complete recovery requiring 6–7 days. In contrast, physical activity decreased only on the first day following withdrawal of the infusion. Thus, the mechanism accounting for the blood pressure decrease must be of a long duration and unrelated to a change in gross physical activity. The results emphasize the value of radiotelemetry for recording blood pressure responses.

Withdrawal-induced antihypertensive effect of vasopressin: role of the L-arginine/nitric oxide pathway

The role of the endothelium-derived relaxing factor (EDRF), nitric oxide (NO), in the withdrawal-induced antihypertensive phenomenon (WAP) of arginine vasopressin (AVP) was studied in conscious unrestrained rats implanted with femoral arterial catheters for the measurement of arterial blood pressure. Cessation of a 3-h intravenous infusion of AVP (20 ng.kg-1.min-1) was followed by a large and long-lasting fall in mean arterial blood pressure below preinfusion control values in spontaneously hypertensive rats (SHR; -47.5 +/- 6.4 mmHg; 1 mmHg = 133.3 Pa) but not in normotensive Wistar-Kyoto (WKY) and Sprague-Dawley (SD) control rats. Chronic treatment of normotensive SD rats with the NO synthesis inhibitor, N omega-nitro-L-arginine (L-NNA; 0.5 g.L-1 in drinking water for 2 weeks), resulted in sustained hypertension. Similar to the SHR model, a large fall in blood pressure (-37.8 +/- 7.7 mmHg) was observed in this model of hypertension following cessation of the AVP infusion. In SHR, inhibition of NO synthesis with L-NNA (0.05 g.L-1 in drinking water for 2 weeks) failed to attenuate the fall in blood pressure following withdrawal of AVP. Chronic treatment with the NO precursor, L-arginine (L-Arg; 1.25 g.L-1 in drinking water for 2 weeks), did not affect the amplitude or the time course of the WAP in SHR. The results indicate that the L-Arg/NO pathway is not essential to the expression of the WAP to AVP in the SHR.

Cardiac output mediates the antihypertensive effect of vasopressin in spontaneous hypertension.

The contribution of cardiac output and total peripheral resistance to the fall in arterial pressure that follows cessation of a 3-h intravenous infusion of arginine vasopressin (AVP; 20 ng.kg-1.min-1) was studied in conscious spontaneously hypertensive rats (SHR) and Wistar-Kyoto (WKY) rats instrumented with radiotelemetric probes for recording of blood pressure and ultrasonic transit-time flow probes for measuring cardiac output. Cessation of a 3-h infusion of AVP resulted in a significant decrease in arterial pressure in SHR (14-17 mmHg below preinfusion control levels) but not in WKY or in vehicle-treated controls. The fall in pressure persisted for several days. The fall in pressure was associated with a large decrease in cardiac output of 22 +/- 2 ml/min below control levels in SHR, and the time course of the cardiac output response over several days approximated the time course of the pressure response. By contrast, total peripheral resistance remained elevated for some time on withdrawal of the AVP infusion. We conclude that the withdrawal-induced antihypertensive phenomenon in SHR is mediated by a fall in cardiac output and not by a decline in total peripheral resistance.

During acute hypercapnia vasopressin inhibits an angiotensin drive to ventilation in conscious dogs

Intravenous infusion of arginine vasopressin (AVP) depresses the slope of the ventilatory response to CO2 during acute hypercapnia. We therefore tested the hypothesis that AVP V1-receptor blockade would increase the slope of the ventilatory response to CO2. After a 20-min control period, an AVP V1-receptor antagonist (d(CH2)5[Tyr(Me)2]AVP) was injected into six conscious resting dogs. Thirty minutes after AVP V1-receptor blockade, dogs were exposed to sequential 20-min periods of 5 and 6.5% inspired CO2 in air. A second protocol (no AVP V1-receptor blockade) was conducted as a control. As predicted, AVP V1-receptor blockade enhanced ventilation during inhalation of 6.5% CO2 in association with an increased metabolic rate and increased plasma angiotensin II (ANG II). In eupneic dogs, stimulation of respiration by AVP V1-receptor blockade is mediated by ANG II. A third protocol with ANG II-receptor blockade (intravenous infusion of saralasin) combined with AVP V1-receptor blockade indicated that ANG II mediated the increase in metabolism and the augmented ventilation during inhalation of 6.5% CO2. We conclude that during acute hypercapnia of sufficient magnitude, and perhaps duration, AVP inhibits an ANG II-mediated stimulation of metabolism and respiration.

Sympathectomy exaggerates antihypertensive effect of vasopressin withdrawal

The role of sympathetic function in the mechanism of the decrease in arterial pressure that follows withdrawal of an intravenous infusion of arginine vasopressin (AVP) in spontaneously hypertensive rats (SHR) was studied by comparing this withdrawal-induced antihypertensive phenomenon (WAP) in rats with intact sympathetic function to those subjected to sympathectomy. Sympathectomy with guanethidine did not lower blood pressure significantly in either SHR or normotensive Wistar-Kyoto (WKY) rats despite a marked impairment of sympathetic function as judged by a dramatic attenuation of blood pressure responses to tyramine and by evidence of denervation supersensitivity to phenylephrine. Cessation of a 3-h intravenous infusion of AVP (20 ng.kg-1.min-1) was associated with large and prolonged decrease in pressure below preinfusion levels in SHR with intact sympathetic function: 5 h after stopping the infusion, pressure was 27 +/- 3 mmHg below preinfusion levels. In sympathectomized SHR, the decrease in pressure after cessation of the AVP infusion was much larger: 5 h after the infusion, pressure was 44 +/- 2 mmHg below preinfusion levels. In contrast to SHR, pressure returned to control levels in WKY with intact sympathetic function after withdrawal of AVP. A small but significant decrease in pressure occurred after withdrawal of AVP in sympathectomized WKY. The results are consistent with the hypothesis that withdrawal of sympathetic activity is a contributing factor or a prerequisite condition for development of a WAP.

Effect of arginine vasopressin and parathyroid hormone-related protein on renal function in the ovine foetus.

1. The effects of intravenous infusions of arginine vasopressin (AVP), parathyroid hormone-related protein (PTHrP) and AVP+PTHrP on renal function in intact ovine foetuses at 100-125 days of gestation were examined. 2. A low dose of AVP (5.5 +/- 0.9 pmol/h) increased plasma AVP concentrations from 0.6 pmol/L to 2.1 +/- 0.4 pmol/L (mean +/- s.e.m; n = 8). This dose caused a significant reduction in free water clearance (CH2O; P < 0.001), without any significant change in fetal arterial blood pressure, glomerular filtration rate (GFR), or the urinary excretion rates of sodium, calcium or 3',5'-cyclic adenosine monophosphate (cAMP). 3. Infusions of PTHrP (1 nmol/h), with or without 1 nmol bolus dose, significantly increased (P < 0.05) urine osmolality (UOSM), but did not synergize with AVP in reducing CH2O. 4. It is concluded that AVP and PTHrP do not act synergistically on the kidney of the intact ovine foetus.

Intermittent sinusoidal heart rate pattern in vagotomized fetal lambs

Our aims were to investigate the relationship between the dose of arginine vasopressin and the pattern and duration of arginine vasopressin-induced sinusoidal fetal heart rate and to elucidate the correlation between intermittent sinusoidal heart rate and fetal sleep cycle. Sinusoidal heart rate pattern was induced by intravenous arginine vasopressin infusion at doses from 2 to 78 mlU/min into 11 chronically instrumented fetal lambs with bilateral cervical vagotomy. Appearance and frequency of sinusoidal heart rate, intermittent sinusoidal heart rate, and persistent sinusoidal heart rate were observed along with fetal tracheal pressure and electrooculogram. Intermittent sinusoidal heart rate response to low, medium, and high doses of arginine vasopressin appeared in 73.3%, 50.0%, and 33.3% of experiments, respectively. Intermittent sinusoidal heart rate appeared more frequently than persistent sinusoidal heart rate with lower doses (p < 0.02). When intermittent sinusoidal heart rate was induced, the incidence of sinusoidal patterns significantly increased during non-rapid-eye-movement sleep in comparison with rapid-eye-movement sleep (p < 0.01). Appearance of sinusoidal heart rate seems to be related to the dose of arginine vasopressin infused. Appearance of sinusoidal heart rate is also influenced by fetal sleep cycle; sinusoidal heart rate is more likely to appear during non-rapid-eye-movement sleep than during rapid-eye-movement sleep. These results support the hypothesis that persistent sinusoidal heart rate correlates with severity of stress.

Whole body vascular capacitance response to vasopressin is mediated by autonomic function

Effects of intravenous infusions of arginine vasopressin (AVP) on whole body vascular capacitance were determined in anesthetized cats when autonomic nervous system function was intact and, in other cats, when reflexes were blocked by the ganglionic blocking agent pentolinium. With the use of the constant cardiac output-reservoir technique, changes in reservoir volume were assumed to reflect reciprocal changes in whole body vascular capacitance. Relationships between the dose of AVP and the plasma concentration of the peptide achieved during infusions were not significantly different in the two groups of animals. Blood pressure responses to AVP were greater, whereas heart rate responses to the peptide were abolished in ganglion-blocked cats. In cats with intact autonomic function, reservoir volume decreased by 1.6, 4.2, and 7.8 ml/kg at AVP doses of 1, 10, and 100 ng.kg-1.min-1, respectively. In contrast, in ganglion-blocked cats, reservoir volume did not change significantly at 1.0 and 10 ng.kg-1.min-1 of AVP, and the highest dose caused a much smaller change in volume (3 ml/kg) than that observed in cats with intact autonomic function (7.8 ml/kg). Systemic compliance was unchanged by AVP in both groups of animals, suggesting that the increases in whole body vascular capacitance were likely due to changes in unstressed volume. The results suggest that reflexively mediated changes in autonomic function increase whole body vascular capacitance during elevations in the circulating levels of AVP to plasma concentrations that are biologically relevant. These findings may explain how AVP decreases cardiac output in animals with an intact autonomic nervous system.

Neurons in area postrema mediate vasopressin-induced enhancement of the baroreflex

Intravenous infusion of arginine vasopressin (AVP) has been shown to enhance baroreflex sensitivity, and this enhancement is dependent on the integrity of the area postrema. However, previous studies did not differentiate a role for cell bodies in the area postrema vs. the dense network of fibers located in and around the lateral and ventral margins of this circumventricular organ. In the present study, baroreflex function was assessed in conscious rabbits by examining heart rate after ramp infusions of phenylephrine (PE) and AVP. The subsequent day, the excitotoxin kainic acid was injected (30 nl initially, with five 15-nl supplemental injections of a 1 ng/nl solution over 1 h) into the area postrema, thus selectively destroying cell bodies. After an 8-day recovery period, baroreflex function was again assessed. The bradycardic response to graded infusion of PE (slope = -2.29 +/- 0.30) was not significantly different after selective lesions of area postrema neurons (slope = -1.88 +/- 0.49). In contrast, the previously enhanced bradycardic response to infusion of AVP (slope = -5.76 +/- 1.02) was significantly attenuated (slope = -2.31 +/- 0.21) to levels similar to that seen with infusion of PE. Thus selective chemical lesions of area postrema neurons block vasopressin-induced enhancement of the baroreflex.

Area postrema and differential reflex effects of vasopressin and phenylephrine in rats

In normal rats, baroreflex inhibitions of heart rate (HR) and splanchnic but not lumbar sympathetic neural activity (SNA) are greater when mean arterial pressure (MAP) is increased by intravenous infusion of arginine vasopressin (AVP) compared with phenylephrine (PE) or methoxamine. In normal rabbits, baroreflex inhibitions of HR and lumbar and renal SNA are all greater when MAP is increased by AVP vs. PE. The differential reflex bradycardic and renal sympathoinhibitory effects of AVP vs. PE in rabbits require an intact area postrema. To determine whether differential reflex effects of AVP vs. PE in rats is selective for HR or inclusive of renal SNA and to examine the role of the rat area postrema in such action, we monitored HR and renal SNA in normal (sham operated, n = 8) and area postrema-lesioned (APX, n = 8) rats under chloralose anesthesia during slow increases in MAP (less than 0.3 mmHg/s; 3 min) induced intravenously by AVP (0-16 mU.kg-1.min-1) and by PE (0-8 micrograms.kg-1.min-1). Reflex inhibition of HR (-delta betas.min-1.delta mmHg-1) was greater when MAP was increased by AVP vs. PE in normal rats (-2.7 +/- 0.5 vs. -1.7 +/- 0.1, P less than 0.05), and this difference was absent in APX rats (-2.5 +/- 0.5 vs. +/- -2.2 +/- 0.4). Similarly, maximum bradycardia (-delta beats/min) by AVP vs. PE was greater in normal rats (-64 +/- 8 vs. -48 +/- 7, P less than 0.05) but not in APX rats (-53 +/- 5 vs. -52 +/- 6).(ABSTRACT TRUNCATED AT 250 WORDS)

Fetal hemodynamic and fetoplacental vascular response to exogenous arginine vasopressin

Fetal hemodynamics and fetoplacental blood flow were measured in chronically instrumented ovine fetuses during intravenous infusion of arginine vasopressin. Vasopressin was infused at rates ranging from 1 to 300 ng/min/kg estimated fetal mass. This range of infusion rates produces plasma arginine vasopressin levels observed throughout a wide range of fetal stress. No maternal effects were observed at any infusion rates used in this investigation. Fetal heart rate declined linearly with the log of the infusion rate. Mean fetal arterial pressure showed a sigmoidal response to log arginine vasopressin infusion rate, reaching a plateau at 30 ng/min/kg. Umbilical vascular resistance increased throughout the entire range of infusion rates. Fetoplacental blood flow decreased with increasing infusion rate but decreased only 4% to 13% throughout the range of infusion rates that produce plasma arginine vasopressin levels commonly observed during fetal stress. Because umbilical vascular resistance continued to rise after arterial pressure reached a plateau, fetoplacental blood flow decreased 31% at the highest infusion rate. However, the plasma vasopressin level associated with this infusion rate is probably in excess of that associated with severe fetal distress. The fetoplacental vascular bed is, therefore, either relatively insensitive to arginine vasopressin, or is capable of autoregulation in the face of high circulating levels of arginine vasopressin.

Arginine vasopressin increases apparent whole body capacity in anesthetized cats

The effects of arginine vasopressin (AVP) on capacitance function were assessed in anesthetized cats by draining blood from the superior and inferior venae cavae into an external reservoir and then returning blood to the right atrium at a constant rate. Under these conditions, changes in reservoir volume were assumed to reflect reciprocal changes in whole body capacity. Intravenous infusions of AVP (1, 10, and 100 ng.kg-1.min-1) that elevated plasma AVP concentrations by approximately 30, 400, and 4,000 fmol/ml were associated with concentration-dependent increases in whole body capacity that ranged between 1.6 and 8 ml/kg. In contrast to AVP, intravenous infusions of angiotensin II (5, 10, and 50 ng.kg-1.min-1) had relatively little influence on capacity, whereas norepinephrine administration (300, 1,000, and 3,000 ng.kg-1.min-1) was associated with dose-dependent decreases in capacity of 4.5-10.3 ml/kg. Virtually the entire increase in whole body capacity to AVP can be accounted for by summation of the predicted contributions of an active reflex venodilatatory component and those of a passive component (arterial and cardiopulmonary compartments). Because systemic compliance (delta reservoir volume/delta venous pressure) was not changed by AVP administration, the contribution of a reflex venodilatatory component must be the result of increases in unstressed vascular volume (contained volume at 0 transmural pressure) as opposed to changes in compliance. These results may explain why AVP decreases cardiac output to a greater extent than either angiotensin II or sympathomimetics and, thus, why AVP is a weaker pressor agent in animals with intact autonomic function.

Effect of the cessation of an infusion of vasopressin in acutely hypophysectomized anaesthetized dogs.

Stimulation of left atrial receptors in dogs anaesthetized with chloralose results in a reflex diuresis and a small decrease in the plasma concentration of vasopressin. It has been suggested that this diuretic response is solely mediated by the antidiuretic hormone, vasopressin (Gauer & Henry, 1976; Ledsome, 1985). The present investigation was designed to determine how these anaesthetized dogs, which are thought to be insensitive to changes in plasma vasopressin, respond to small decreases in plasma vasopressin similar to those observed during stimulation of left atrial receptors. In the event it was shown for the first time that it is possible to obtain a water diuresis in an anaesthetized animal in response to a small fall in the concentration of plasma vasopressin. In order to produce changes in plasma vasopressin similar to those seen during stimulation of left atrial receptors the pituitary gland was removed and an intravenous infusion of arginine vasopressin was given in eleven dogs anaesthetized with chloralose; a small decrease in plasma vasopressin was then produced by replacing the vasopressin with an infusion of saline for 30 min. A decrease in the plasma concentration of 1.29 pg cm-3 from a control concentration of 1.85 pg cm-3 resulted in a 96.7% increase in urine flow. The fall in concentration of vasopressin consequent upon stimulation of atrial receptors could, therefore, explain the water diuresis in the anaesthetized dog preparation.(ABSTRACT TRUNCATED AT 250 WORDS)

Central nervous system mechanisms involved in inhibition of renal sympathetic nerve activity induced by arginine vasopressin.

Previous studies have suggested that intravenous infusion of arginine vasopressin (AVP) inhibits sympathetic nerve activity (SNA) in rabbits by its action at the brainstem. This study aimed to determine, first, whether this action of AVP depended on functioning baroreflex mechanisms. The second aim was to determine the role of the nucleus tractus solitarii (NTS) in mediating this action of AVP. Experiments were performed in rabbits anesthetized with alpha-chloralose. Intravenous infusions of AVP (1, 3, and 10 mU/kg/min) resulted in progressive inhibition of renal SNA in rabbits with intact arterial baroreceptors and vagal afferents as well as in rabbits with sinoaortic denervation and bilateral vagotomy. The magnitudes of renal SNA inhibition evoked with AVP were comparable in the two groups. Renal SNA inhibition evoked with AVP at doses of 1 and 3 mU/kg/min in rabbits after sinoaortic denervation and vagotomy was totally blocked by chemical lesions with kainic acid of the bilateral NTS or the area postrema. Lesions of the NTS or the area postrema markedly attenuated (by about 60%) but did not totally block the response evoked with AVP at a dose of 10 mU/kg/min. AVP microinjected directly into the NTS did not evoke changes in renal SNA or arterial pressure, whereas AVP microinjected into the area postrema suppressed renal SNA. These results suggest that intravenous AVP at lower doses inhibited renal SNA by causing excitation of the NTS neurons, and this action of AVP did not depend on functioning baroreflex mechanisms. The second suggestion is that the NTS was unlikely to be the site where AVP directly interacted but instead received a neural connection, presumably from the area postrema, where AVP might directly interact.

Withdrawal-induced antihypertensive effect of vasopressin in Doca-salt hypertension.

Arterial pressure and heart rate were recorded in three groups of conscious unrestrained rats before, during and after a three-hour intravenous infusion of arginine vasopressin (AVP; 20 ng/kg/min). Before infusion of AVP, basal arterial pressure was 152 +/- 3.2 mm Hg for the Doca-salt hypertensive group, 117 +/- 3.2 mm Hg for the uninephrectomized control group, and 111 +/- 2.1 mm Hg for the sham-operated control group. The changes in arterial pressure at each of the time points during the three-hour infusion of AVP were not significantly different among the three groups. Cessation of the AVP infusion was associated with a dramatic and prolonged fall of arterial pressure below preinfusion basal levels in the Doca-salt hypertensive group: pressure was 58 +/- 5.0 mm Hg below basal levels within 60 minutes of stopping the infusion and was still 45 +/- 5.6 mm Hg below four hours later. Pressure in this group was 107 +/- 5.7 mm Hg five hours after stopping the infusion. In contrast, the fall in pressure in the two control groups was small. Five hours after stopping the infusion, pressure was 108 +/- 2.3 mm Hg in the uninephrectomized group and 102 +/- 1.7 mm Hg in the sham-operated group. Thus, five hours after stopping the infusion, blood pressures among the three groups were not significantly different. The Doca-salt hypertensive group had been rendered normotensive.(ABSTRACT TRUNCATED AT 250 WORDS)